CTI BioPharma

CTI BioPharma Corp. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of novel targeted therapies for blood-related cancers. It focuses on evaluating pacritinib, its sole product candidate currently in active development, for the treatment of adult patients with myelofibrosis. The company was founded by James A. Bianco, Jack W. Singer, and Louis A. Bianco in September 1991 and is headquartered in Seattle, WA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CTI BioPharma Corp. a biopharmaceutical company, develops, acquires, and commercializes oncology products for cancer treatment. Its development portfolio includes Pixantrone, a phase III trial product, for non-Hodgkin's lymphoma; Brostallicin, which is in a first-line Phase II study for the treatment of sarcoma; and OPAXIO, a chemotherapeutic agent for the potential treatment of non-small cell lung, ovarian, and other cancers. It has collaboration and licensing arrangements with Novartis International Pharmaceutical, Ltd.; and PG-TXL Company, L.P.

CTI BioPharma has finally fulfilled its long sought goal of FDA approval for its VONJO (JAK inhibitor pacritinib) in treatment of myelofibrosis. Armed with a wholesale cost of ~$19,500 month, VONJO could be a blockbuster.

CTI BioPharma: One Trick Pony Ready To Perform

CTI BioPharma's Pacritinib has been conditionally approved. It has critical differentiations with Incyte's Jakafi.

CTI BioPharma: Approval Is Great, Now There's The Follow Through

An analyst launches coverage of the company with an unequivocal buy recommendation.

Why CTI BioPharma Stock Blasted 18% Higher Today

SEATTLE , June 10, 2022 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced two scientific poster presentations from the Company's pacritinib clinical program at the European Hematology Association (EHA) 2022 Congress, being held in Vienna, Austria, June 9-12, 2022. "Our presentions today demonstrate that full dose pacritinib achieved higher response rates and a similar, manageable safety profile compared to lower-dose ruxolitinib in patients with myelofibrosis who have moderate or severe thrombocytopenia," said Adam Craig, President and Chief Executive Officer of CTI BioPharma.

CTI BioPharma Presents Pivotal Data from Pacritinib Program at the European Hematology Association (EHA) 2022 Congress

SEATTLE , June 2, 2022 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will provide a corporate overview at two upcoming investor conferences in New York City. Presentation details: Event: Jefferies Healthcare ConferenceDate: Friday, June 10, 2022 Time: 10:00 a.m.

CTI BioPharma to Present at Upcoming June Conferences

SEATTLE , May 26, 2022 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced a poster presentation from the Company's pacritinib program at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago and virtually, June 3-7, 2022. "These data reinforce pacritinib's role as a safe, differentiated JAK inhibitor.

CTI BioPharma Presents Pivotal Data from Pacritinib Program at the 2022 American Society of Clinical Oncology Annual Meeting

A strong launch for the company's first commercialized drug drew a cheer from investors.

Why CTI Biopharma Stock Is Surging Today

CTI BioPharma Corp. (NASDAQ:CTIC ) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Adam Craig - CEO and President of CTI BioPharma James Fong - SVP and Chief Commercial Officer David Kirske - EVP, CFO and Secretary Conference Call Participants Robert Hazlett - BTIG Ben Burnett - Stifel Gil Blum - Needham Boris Peaker - Cowen Thomas Flaten - Lake Street Capital Operator Good afternoon. Thank you for standing by.

CTI BioPharma Corp. (CTIC) CEO Adam Craig on Q1 2022 Results - Earnings Call Transcript

CTI BioPharma (CTIC) delivered earnings and revenue surprises of -5.71% and 6.74%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

CTI BioPharma (CTIC) Reports Q1 Loss, Tops Revenue Estimates

– Strong U.S. commercial launch of VONJO™  (pacritinib) underway following accelerated FDA approval for the treatment of adult patients with Myelofibrosis and Thrombocytopenia – – VONJO (pacritinib) net product revenue of $2.3 million in less than one month following launch, exceeding initial Company expectations – – VONJO included as recommended first- and second-line treatment in NCCN ® Clinical Practice Guidelines in Oncology for Myeloproliferative Neoplasms – – Abstracts accepted at ASCO 2022 and EHA 2022 in June – – Management to host conference call today at 4:30 p.m. ET – SEATTLE , May 12, 2022 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the first quarter ended March 31, 2022.

CTI BioPharma Reports First Quarter 2022 Financial Results

SEATTLE , May 10, 2022 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced one poster presentation from the Company's pacritinib program at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago and virtually, June 3-7, 2021. The details of the poster presentation are as follows: Abstract Title: Risk-adjusted safety analysis of pacritinib (PAC) in patients (pts) with myelofibrosis (MF) Abstract Number: 7058 Session Name: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant Session Date: Saturday, June 4, 2022 Presentation Time: 8:00 – 11:00 a.m.

CTI BioPharma Announces Presentation at the 2022 American Society of Clinical Oncology Annual Meeting

CTIC is undervalued and a strong buy for new investors. The current share price of ~$5.63 does not reflect the potential of outsized returns to patient, long-term investors. Under conservative assumptions, my DCF model shows the equity value of CTIC at $17 per fully diluted share, an ~3.2x ROI from current levels.

CTI BioPharma - 3.2x Potential Upside On A De-Risked Asset

SEATTLE , April 28, 2022 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management plans to report its first quarter 2022 financial results on Thursday, May 12, 2022, after the close of the U.S. financial markets. Following the announcement, members of the management team will host a conference call and webcast to discuss the results and provide a general corporate update at 4:30 p.m.

CTI BioPharma to Report First Quarter 2022 Financial Results on May 12, 2022

Camber Energy

Didi Global

Imperial Petroleum

Medavail Holdings Inc

UP Fintech Holding

22nd Century Group

Penny stocks with unusual options activity today. Are they on your watch list right now?

7 Top Penny Stocks To Watch With Unusual Options Activity In April 2022

VONJO is the only approved JAK inhibitor recommended by NCCN for myelofibrosis patients regardless of platelet count SEATTLE , April 14, 2022 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced that VONJO™ (pacritinib), its novel oral kinase inhibitor with specificity for JAK2 and IRAK1, without inhibiting JAK1, has been included as a recommended treatment in the latest National Comprehensive Cancer Network ®  (NCCN ® ) Clinical Practice Guidelines in Oncology for Myeloproliferative Neoplasms. "We are grateful that NCCN acted quickly to include VONJO with a Category 2A designation in its Clinical Practice Guidelines in Oncology as a first line treatment for high-risk patients with myelofibrosis with platelet counts

NCCN Guidelines® Recommend VONJO™ (pacritinib) for the Treatment of Myeloproliferative Neoplasms

SEATTLE , April 6, 2022 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will participate in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference at 1:30 p.m. ET. The conference will be held in a virtual meeting format.

CTI BioPharma to Present at the 21st Annual Needham Virtual Healthcare Conference

– VONJOTM (pacritinib) Approved by FDA for the Treatment of Adult Myelofibrosis Patients with Myelofibrosis and Thrombocytopenia; Commercial Launch Underway – – $60 Million Payment from DRI Healthcare Trust Triggered by FDA Approval under the Terms of the Previously Announced Debt and Royalty Transaction – SEATTLE , March 31, 2022  /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the fourth quarter and full year ended December 31, 2021. "VONJO's recent FDA approval establishes a new standard of care for myelofibrosis patients suffering from cytopenic myelofibrosis.

CTI BioPharma Reports Fourth Quarter and Full Year 2021 Financial Results

Is it a good or bad thing when a stock experiences a golden cross technical event?

Should You Buy CTI BioPharma (CTIC) After Golden Cross?

Coupa Software

Westport Fuel Systems

After markets closed Thursday, electric truck maker Rivian reported a wider-than-expected loss and lower-than-expected revenue, topped off with a downside outlook for both production and revenue.

Earnings Previews: Coupa Software, CTI BioPharma, Westport Fuel

Coeur Mining

Document Security Systems

Can these penny stocks climb this month? The post Hot Penny Stocks to Watch in March 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Penny Stocks to Watch in March 2022

SEATTLE, March 2, 2022 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will provide a corporate overview at the Cowen Annual Healthcare Conference at 1:30 p.m. ET. The conference will be held in a virtual meeting format.

CTI BioPharma to Present at the Cowen 42nd Annual Healthcare Conference

Farmmi

Mullen Automotive

What you need to know about trading penny stocks on March 1st, 2022 The post Trading Penny Stocks? Top Stock Market News for March 1st, 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Trading Penny Stocks? Top Stock Market News for March 1st, 2022

The CTI BioPharma Corp (NASDAQ: CTIC) stock increased by over 75% pre-market today. This is why.

CTI BioPharma (CTIC) Stock: Why It Surged Today

We are initiating with CTI BioPharma with a buy rating with a TP of USD 7.6 if pacritinib is approved.

CTI BioPharma: A Speculative Buy Into The PDUFA Date

SEATTLE, Feb. 28, 2022 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced the U.S. Food and Drug Administration (FDA) has approved VONJO (pacritinib) for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 109/L. VONJO is a novel oral kinase inhibitor with specificity for JAK2 and IRAK1, without inhibiting JAK1.

News for CTI BioPharma Stock (CTIC)